The largest database of trusted experimental protocols
> Disorders > Mental or Behavioral Dysfunction > Presenile Dementia

Presenile Dementia

Presenile Dementia: A form of dementia that occurs before the age of 65, often presenting with cognitive impairments, personality changes, and difficulties with daily activities.
This early-onset condition can have diverse etiologies, including Alzheimer's disease, vascular disorders, and other neurological disorders.
Accurate diagnosis and effective management of presenile dementia are crucial for improving patient outcomes and quality of life.
Reserach in this field aims to enhance understaing of risk factors, develop better diagnostic tools, and identify novel therapies to slow disease progression.

Most cited protocols related to «Presenile Dementia»

Cognitive domain and test selection were based on a combination of methods evolving from regular meetings of the CTF. A subcommittee was formed to specifically undertake the design of the neuropsychological test battery, to bring essential issues to the larger group and to interface with the ADCs. Three overriding criteria governed decisions for selecting domains and tests. The first was the mandate for the UDS to initially focus on cognitive markers of aging and of dementia associated with AD, the second was to minimize burden on the ADCs and their subjects, and the third was to accommodate the continuity of measures that ADCs have previously collected. A fourth principle that emerged after an initial set of domains and tests was identified was the need to overlap with other ADC initiatives such as the Late Onset Alzheimer’s Disease (LOAD) Genetics study and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Because of the need to focus on the cognitive continuum from aging without dementia, to MCI, to AD, cognitive domains were selected for their sensitivity to age-related change in cognition [17 (link)–29 (link)] sensitivity to the demonstrated primary cognitive impairments in AD [30 –36 (link)], ability to measure change over time and to stage AD [37 (link)], and ability to predict progression from MCI to AD [38 (link)–41 ]. Additional criteria for test selection included applicability of the measures to different educational levels, to diverse racial/ethnic minority groups and to Spanish-speaking populations. A Spanish translation of the UDS has been completed and is available on the NACC website (https://www.alz.washington.edu).
The minimization of burden, an issue of feasibility, had to figure centrally in test selection. Many ADCs have been conducting research for over 20 years. Well-established protocols and longitudinal research projects could be disrupted by the need to significantly alter assessment and enrollment methods, notwithstanding the added time burden for subjects and their study partners. Thus, with input from the ADCs, the CTF concluded that the neuropsychological battery should not add more than 30 minutes to existing protocols at each Center. One implication of this principle was that tests already in use by all or most ADCs would be high on the list of candidates for inclusion.
The CTF conducted several surveys of the ADCs to gather data about their ongoing assessment practices including, among other variables: 1) cognitive domains tested; 2) specific instruments and versions, for tests with multiple forms; 3) populations of subjects followed (i.e., disease and control groups; clinic and/or community samples); 4) frequency of subject visits. Once these data were acquired, the most commonly tested domains and the most commonly used specific measures were identified and comments and approval were solicited from the ADCs.
Publication 2009
Cognition Disease Progression Disorders, Cognitive Ethnic Minorities Hispanic or Latino Hypersensitivity Neuropsychological Tests Population Group Presenile Dementia Racial Groups SET Domain
For most diseases and injuries, processed data are modelled using standardised tools to generate estimates of each quantity of interest by age, sex, location, and year. There are three main standardised tools: Cause of Death Ensemble model (CODEm), spatiotemporal Gaussian process regression (ST-GPR), and DisMod-MR. Previous publications2 (link), 3 (link), 12 and the appendix provide more details on these general GBD methods. Briefly, CODEm is a highly systematised tool to analyse cause of death data using an ensemble of different modelling methods for rates or cause fractions with varying choices of covariates that perform best with out-of-sample predictive validity testing. DisMod-MR is a Bayesian meta-regression tool that allows evaluation of all available data on incidence, prevalence, remission, and mortality for a disease, enforcing consistency between epidemiological parameters. ST-GPR is a set of regression methods that borrow strength between locations and over time for single metrics of interest, such as risk factor exposure or mortality rates. In addition, for select diseases, particularly for rarer outcomes, alternative modelling strategies have been developed, which are described in appendix 1 (section 3.2).
In GBD 2019, we designated a set of standard locations that included all countries and territories as well as the subnational locations for Brazil, China, India, and the USA. Coefficients of covariates in the three main modelling tools were estimated for these standard locations only—ie, we ignored data from subnational locations other than for Brazil, China, India, and the USA (appendix 1 section 1.1). Using this set of standard locations will prevent changes in regression coefficients from one GBD cycle to the next that are solely due to the addition of new subnational units in the analysis that might have lower quality data or small populations (appendix 1 section 1.1). Changes to CODEm for GBD 2019 included the addition of count models to the model ensemble for rarer causes. We also modified DisMod-MR priors to effectively increase the out-of-sample coverage of uncertainty intervals (UIs) as assessed in simulation testing (appendix 1 section 4.5).
For the cause Alzheimer's disease and other dementias, we changed the method of addressing large variations between locations and over time in the assignment of dementia as the underlying cause of death. Based on a systematic review of published cohort studies, we estimated the relative risk of death in individuals with dementia. We identified the proportion of excess deaths in patients with dementia where dementia is the underlying cause of death as opposed to a correlated risk factor (appendix 1 section 2.6.2). We changed the strategy of modelling deaths for acute hepatitis A, B, C, and E from a natural history model relying on inpatient case fatality rates to CODEm models after predicting type-specific acute hepatitis deaths from vital registration data with specified hepatitis type.
DisMod-MR was used to estimate deaths from three outcomes (dementia, Parkinson's, and atrial fibrillation), and to determine the proportions of deaths by underlying aetiologies of cirrhosis, liver cancer, and chronic kidney disease deaths.
Full text: Click here
Publication 2020
Alzheimer's Disease Atrial Fibrillation Cancer of Liver Chronic Kidney Diseases Dementia Hepatitis A Injuries Inpatient Liver Cirrhosis Patients Population Group Presenile Dementia
Archival data were reviewed from 4248 consecutive participants recruited into the Mayo Clinic Alzheimer's Disease Research Center (ADRC) and Alzheimer's Disease Patient Registry (ADPR) database. The Rochester Mayo ADPR is responsible for recruiting dementia patients and non-demented control subjects for studies on the progression of Alzheimer's disease through the Department of Community and Internal Medicine and does not operate in Jacksonville. The Rochester and Jacksonville ADRC sites acquire dementia patients from Behavioral Neurology. The Jacksonville ADRC site also recruits community controls via churches and community agencies. The same inclusion/exclusion criteria are applied for normal controls across both recruitment sites and has been published extensively through analyses of the MOANS16 (link)-19 and MOAANS20 (link)-22 (link) data. Patients with memory concerns raised by either the patient themselves, a family member, or a physician undergo a comprehensive neurological evaluation and neuropsychological testing to confirm or rule out dementia and Alzheimer disease.
A total of 1141 individuals with 16 or more self-reported years of education were identified. The sample included 1064 (93%) individuals who self-identified as Caucasian and 77 (7%) who self-identified as African-American. Of the 1141 participants, 658 individuals (242 males and 416 females) had no dementia and were considered cognitively normal (see Ivnik et al.19 for full criteria used to define normal cognition). The remaining 307 (164 males and 143 females) carried diagnoses of dementia established via consensus among ADRC investigators and based on published diagnostic criteria. Diagnoses included 202 (66%) patients with probable Alzheimer's disease, 48 (16%) with dementia with Lewy bodies, 18 (6%) with frontotemporal dementia, 13 (4%) with vascular dementia, and 25 (8%) with other dementia etiologies. A sample of 176 patients (106 males and 70 females) diagnosed with Mild Cognitive Impairment (MCI) was also included for comparison purposes.
The total sample included 512 (45%) males and 629 (55%) females, with a mean age of 75.9 (SD=7.2) years and a mean self-reported education of 17.1 (SD=1.5) years. There were no significant between-group differences (dementia vs. no dementia) in terms of age, gender, or education.
While the MMSE was available in diagnostic meetings, the diagnosis of dementia (and particular subtype) was arrived at via consensus-based judgment taking into account information from the neurological examination, clinical interview, lab results, imaging, informant ratings of activities of daily living (ADLs), as well as neuropsychological test data. Therefore, the MMSE had minimal impact on diagnostic decisions in the dementia cohort and was not considered at all as part of the determination of control status.
Publication 2008
African American Alzheimer's Disease Caucasoid Races Cognition Cognitive Impairments, Mild Dementia, Vascular Diagnosis Disease Progression Family Member Females Lewy Body Disease Males Memory Mini Mental State Examination Neurologic Examination Neuropsychological Tests Patients Physicians Pick Disease of the Brain Presenile Dementia
The primary objective of the A4 study is to test the hypothesis that solanezumab, administered as a 400-mg intravenous infusion every 4 weeks for 168 weeks, will slow cognitive decline compared with placebo in participants with preclinical AD. This objective will be assessed using a mixed model of repeated measures (MMRM) analysis of change in the ADCS-PACC score. The specific hypothesis of the A4 study is that there will be less of a decrease in the ADCS-PACC score at the end of the treatment period for participants treated with solanezumab than for participants treated with placebo.
Based on a review of the literature for cohort studies in “normal controls” who progressed to mild cognitive impairment or Alzheimer dementia, we determined that a composite measure sensitive to change in preclinical AD would likely require assessment of 3 key domains: episodic memory, executive function, and orientation. Previous studies19 (link)–21 (link) have reported evidence that both list learning and paragraph recall (measures of episodic memory) tend to decline 7 to 10 years prior to the diagnosis of MCI or Alzheimer dementia. Recent data from amyloid imaging studies25 (link)–29 (link) have reported a decline in multiple cognitive domains looking retrospectively at cognitive trajectories over 8 to 10 years prior to PET amyloid imaging22 (link)–24 (link) and prospectively over 1- to 3-year longitudinal follow-up.
Based on this review, we propose a composite of 4 measures that are well established as showing sensitivity to decline in prodromal and mild dementia, and with sufficient range to detect early decline in the preclinical stages of the disease. The ADCS-PACC includes:

The Total Recall score from the Free and Cued Selective Reminding Test (FCSRT) (0–48 words),20 (link),30 (link)

The Delayed Recall score on the Logical Memory IIa sub-test from the Wechsler Memory Scale (0–25 story units),31

The Digit Symbol Substitution Test score from the Wechsler Adult Intelligence Scale–Revised (0–93 symbols),32 and

The MMSE total score (0–30 points).33 (link)

The composite score is determined from its components using an established normalization method.34 (link) Each of the 4 component change scores is divided by the baseline sample standard deviation of that component, to form standardized z scores. These z scores are summed to form the composite. Thus, a change of 1 baseline standard deviation on each component would correspond to a 4-point change on the composite. In the A4 study, the ADCS-PACC will be administered at baseline and at 24, 48, 72, 96, 120, 144, and 168 weeks, alternating between 3 test versions.
Publication 2014
Alzheimer's Disease APP protein, human Cognition Delayed Memory Diagnosis Disorders, Cognitive Executive Function Fingers Hypersensitivity Intravenous Infusion Memory, Episodic Mental Recall Mini Mental State Examination Placebos Presenile Dementia solanezumab
Participants in this study included 93 patients with AD and 43 patients with amnestic MCI (aMCI) who were recruited from the Memory Disorder Clinic at the Samsung Medical Center in Seoul, Korea from November 2005 to January 2007. All patients with AD met the criteria for probable AD proposed by the National Institute of Neurological and Communicative Diseases and Stroke and Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) (3 (link)). The aMCI patients were diagnosed according to the criteria proposed by Peterson et al. (4 (link)): 1) subjective memory complaint as described by the patient and/or caregiver, 2) normal general cognitive function, as defined by a score of 24 or greater on the Korean version of Mini-Mental State Examination (MMSE), 3) ability to participate in normal activities of daily living (ADL), judged clinically and by an ADL scale, 4) objective memory decline below the 16th percentile on neuropsychological tests, and 5) non-conformance to clinical criteria for diagnosis of dementia.
All patients underwent a comprehensive evaluation consisting of a detailed medical history, neurological examinations, and a neuropsychological evaluation (SNSB). Additionally, laboratory tests were used to confirm that there were no secondary causes for dementia or cognitive impairment. Magnetic Resonance Imaging (MRI) was performed on all patients, and all patients with structural brain lesions or severe white matter ischemia (caps or band >10 mm and deep white lesion >25 mm) were excluded. Patients who were illiterate were also excluded, regardless of formal education status.
The normal control (NC) group consisted of 77 healthy spouses or caregivers of patients from the memory disorder clinic. All controls were screened for neurological and psychiatric illnesses, and those who were identified to have any of these illnesses were excluded from the study. All subjects in the NC group met the criteria for healthy controls proposed by Christensen et al. (5 ) and did not have dementia as defined by the score below 8 points on the Korean Dementia Screening Questionnaire (KDSQ) (6 ) as well as by an ADL score less than 8 on Seoul Instrumental Activities of Daily Living (S-IADL) (7 ).
The three groups included in this study did not differ significantly in age, education level, and gender. In terms of Clinical Dementia Rating (CDR) scores (8 (link)), all participants in the NC group had a CDR score of 0; all patients in the MCI group had a CDR score of 0.5; and of the participants in the AD group 35 had a CDR score of 0.5 (mild stage, 38%), 42 had a CDR score of 1 (mild to moderate stage, 45%), and 16 had a CDR score of 2 (moderate stage, 17%). Among patients with AD, the CDR groups did not differ in age, education level, and gender. We obtained informed consents from all the patients and controls, and this study was approved by the Institutional Review Board of Samsung Medical Center (2005-02-008).
Publication 2010
Alzheimer's Disease Brain Cerebrovascular Accident Cognition Communicative Disorders Diagnosis Disorders, Cognitive Ethics Committees, Research Gender Ischemia Koreans Memory Memory Disorders Mental Disorders Mini Mental State Examination Neurologic Examination Neuropsychological Tests Patients Presenile Dementia White Matter

Most recents protocols related to «Presenile Dementia»

Observational studies (cross-sectional or longitudinal cohort studies) were included if they reported on community-dwelling older adults aged 60 years and above. This age cutoff point was selected because studies on frailty typically included participants aged 60 years and above (27 (link)). Cross-sectional, prospective cohort studies were included due to the small number of longitudinal studies that reported on the association between cognitive frailty and disability. Cognitive frailty was defined by the presence of frailty or prefrailty, and concurrent cognitive impairment was identified using validated physical frailty and cognitive assessments. A preliminary literature search has identified that most studies on cognitive frailty have slightly modified the definition of cognitive frailty by the consensus group, defining this condition with the presence of mild cognitive impairment instead of a CDR of 0.5 with the exclusion of concurrent Alzheimer’s disease or other dementias, and physical frailty using the modified Fried frailty phenotype (28 (link)). Thus, the utilization of CDR was not compulsory for study inclusion in this review if a validated cognitive assessment tool was reported. Studies must report the association between cognitive frailty and functional disability (ADL or IADL, mobility, physical function).
Studies were excluded if they included hospitalized or institutionalized older adults or those with neurological disorders or dementia. Conference abstracts, reviews, randomized controlled trials, protocols, and studies published in other languages besides English were excluded. Study titles and abstracts were screened based on the inclusion/exclusion criteria, and full texts of relevant studies were screened for eligibility. Data were extracted using a piloted data extraction form, including study and participant characteristics, frailty assessment and classification, and corresponding disability outcomes and measurement. Data extraction was conducted by 1 reviewer (K.F.T.) and checked by the second reviewer (S.W.H.L.), with discrepancies resolved by consensus.
Full text: Click here
Publication 2023
Aged Alzheimer's Disease Cognition Cognition Disorders Compulsive Behavior Conferences Dementia Disabled Persons Disorders, Cognitive Eligibility Determination Nervous System Disorder Phenotype Physical Examination Presenile Dementia Range of Motion, Articular
We formulated the prediction of dementia as a binary classification problem (dementia, control); therefore, evaluation metrics, such as accuracy, F1-score, balanced accuracy, precision, specificity and sensitivity, were used to measure the performance of the subsets of features. The following evaluation metrics were used:

True positives (TP): number of dementia cases that were correctly classified.

False positives (FP): number of healthy subjects incorrectly classified as dementia cases.

True negatives (TN): number of healthy subjects correctly classified.

False negatives (FN): number of dementia cases incorrectly classified as healthy subjects.

Accuracy (%): the proportion of correct classifications among total classifications:

Accuracy=TP+TNn
where n is the number of total classifications per test.

Sensitivity (%): The proportion of correctly classified dementia cases.

Sensitivity=TPTP+FN

Specificity (%): The proportion of correctly classified healthy subjects.

Specificity=TNTN+FP

Precision: The proportion of subjects classified as dementia cases who have dementia.

Precision=TPTP+FP

F1-score (F-measure) (%): Harmonic mean of precision and sensitivity.

F1=2×Sensitivity×PrecisionSensitivity+Precision=TPTP+FP+FN/2
Full text: Click here
Publication 2023
Healthy Volunteers Hypersensitivity Presenile Dementia TpTp
We attempted the classification of dementia status in 146 samples after removing missing values from the 177 that were used in the feature selection process. The 146 samples had a slight class imbalance, with 89 demented versus 57 non-demented patients. Before training our models, we randomly selected 57 patients from the demented group using the sample() function from the random module in Python3. Then, the rows were shuffled using sklearn.utils version 0.22.2.post1. As a result, 114 samples were utilized after balancing the class label. The 32 samples were held out for final assessment. The hippocampal tau stage feature, which had 50% missing values, was dropped during the training process. Age and brain weight were removed before training the models, ending up with 22 features and 114 samples for classification. The dataset was split into a training set of 70% (80 samples) and a testing set of 30% (34 samples).
Seven classification algorithms were trained to classify individuals’ dementia status from the 22 top-ranked features. Scikit-learn version 0.22.2.post1 was used to implement and train the ML classifiers, and then measure their classification performance. Logistic regression was implemented using the sklearn.linear_model package where penalty was set to 12, the regularization parameter C was set to 1, the maximum number of iterations taken for the solvers to converge was set to 2000, and other parameters were set to default values. A decision tree classifier was implemented using the sklearn.tree package. K-nearest neighbors classifier was implemented using the sklearn.neighbors with the number of neighbors set to 5, the function “uniform weights” used for prediction, the “Minkowski” distance metric utilized for the tree, and with other parameters were set to default values. The linear discriminant analysis classifier was implemented using the sklearn.discriminant_analysis package with singular value decomposition for solver hyperparameter and other parameters were set to default values. The Gaussian naïve Bayes classifier was implemented using sklearn.naive_bayes. The support vector machine with a radial basis function kernel (SVM-RBF) was implemented using sklearn.svm with the regularization parameter C set to 1, the kernel coefficient gamma = “scale” and other parameters were set to default values. The support vector machine with a linear kernel (SVM-LINEAR) was implemented using the sklearn.svm package with regularization parameter C set to 1, with a “linear” kernel, gamma coefficient “scale” and other parameters were set to default. The sklearn.metrics package was used to report classification performance. Training and performance evaluation were performed 500 times, from which the average performance measure was calculated as overall performance. Accuracy, balanced accuracy, F1-score, precision, sensitivity and specificity utilizing regression plots were measures used for performance. ML models and feature selection libraries were built using Python 3.7.3.
Full text: Click here
Publication 2023
ARID1A protein, human Brain Gamma Rays Maritally Unattached Patients Presenile Dementia Python Trees
The selection of neuropathology features that were informative of dementia involved several steps (Fig. 1). We first obtained access to and downloaded the CFAS dataset following review and ethics approval by the CFAS management committee. Accordingly, a re-coding of available neuropathological features was performed to categorize and label them into distinct categories (tau, Aβ, demographics, etc.). We then applied supervised learning and feature selection techniques based on multiple filter-based methods. Features were ranked based on their importance and the most informative features were determined. The smallest subset of features that can classify dementia most accurately was identified using several ML classifiers. Finally, we examined misclassified cases in relation to the neuropathology features and linked the associations with other non-standard pathologies.

Methodology for classification of dementia. The methodology for the classification of dementia followed three stages: design, implementation and evaluation. First, we pre-processed and assessed feature-feature correlation after acquiring access to neuropathology and clinical data from CFAS. We then applied feature ranking methods to rank and filter all neuropathology features. Next, classifiers benchmarked with different subsets of features were selected according to their rankings. Finally, we compared cases that were consistently misclassified and evaluated brain attributes associated with these cases in order to improve machine learning

Full text: Click here
Publication 2023
Brain Ethics Committees Open Reading Frames Presenile Dementia
Dementia status at death for each respondent was determined based on interviews/assessments during the last years of the respondent’s life. This included using the full Geriatric Mental State-Automated Geriatric Examination for Computer Assisted Taxonomy diagnostic algorithm, the Diagnostic and Statistical Manual of Mental Disorders (third edition-revised), interviews with the informants after the respondent’s death and the cause of death. Respondents were assessed as having no dementia at death if they had not been identified with dementia at their last interview less than 6 months before death or if they did not have dementia identified at the last interview and the retrospective interview showed no dementia at death. Bayesian analysis was used to estimate the probability of dementia when the last interviews were more than 6 months before death, and no record of having dementia at the interview and no retrospective informant interview (RINI) [5 (link), 33 (link)]. A total of 107 of the 186 subjects had a diagnosis of dementia, which represented approximately 58% of the cohort. Of these 107 cases, 72 were women and 35 were men; their median ages were 89 and 88, respectively. There was a balanced gender ratio (37 females and 33 males) for participants dying without dementia (median age 85 and 79, respectively). The Consortium to Establish a Registry for Alzheimer’s disease (CERAD) criterion determined that in 64 out of the 107 cases (60.0%), Alzheimer’s disease was the definite, probable or possible cause of the observed symptoms.
Full text: Click here
Publication 2023
Alzheimer's Disease Diagnosis Females Males Presenile Dementia Respiratory Diaphragm Woman

Top products related to «Presenile Dementia»

Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in United States, Denmark, Austria, United Kingdom, Japan, Canada
Stata version 14 is a software package for data analysis, statistical modeling, and graphics. It provides a comprehensive set of tools for data management, analysis, and reporting. Stata version 14 includes a wide range of statistical techniques, including linear regression, logistic regression, time series analysis, and more. The software is designed to be user-friendly and offers a variety of data visualization options.
Sourced in United States, United Kingdom, Austria, Denmark
Stata 15 is a comprehensive, integrated statistical software package that provides a wide range of tools for data analysis, management, and visualization. It is designed to facilitate efficient and effective statistical analysis, catering to the needs of researchers, analysts, and professionals across various fields.
Sourced in United States, United Kingdom, Denmark, Austria, Belgium, Spain, Australia, Israel
Stata is a general-purpose statistical software package that provides a comprehensive set of tools for data analysis, management, and visualization. It offers a wide range of statistical methods, including regression analysis, time series analysis, and multilevel modeling, among others. Stata is designed to facilitate the analysis of complex data sets and support the entire research process, from data import to report generation.
Sourced in United States, Japan, Austria, Germany, United Kingdom, France, Cameroon, Denmark, Israel, Sweden, Belgium, Italy, China, New Zealand, India, Brazil, Canada
SAS software is a comprehensive analytical platform designed for data management, statistical analysis, and business intelligence. It provides a suite of tools and applications for collecting, processing, analyzing, and visualizing data from various sources. SAS software is widely used across industries for its robust data handling capabilities, advanced statistical modeling, and reporting functionalities.
Sourced in United States, Austria, United Kingdom, Cameroon, Belgium, Israel, Japan, Australia, France, Germany
SAS v9.4 is a software product developed by SAS Institute. It is a comprehensive data analysis and statistical software suite. The core function of SAS v9.4 is to provide users with tools for data management, analysis, and reporting.
Sourced in United States, United Kingdom, Austria
Stata 16 is a comprehensive statistical software package designed for data analysis, management, and visualization. It provides a wide range of tools and functionalities for researchers, academics, and professionals working with quantitative data. Stata 16 offers advanced statistical methods, data manipulation capabilities, and flexible programming features to support various analytical tasks.
Sourced in United States, Denmark, United Kingdom, Belgium, Japan, Austria, China
Stata 14 is a comprehensive statistical software package that provides a wide range of data analysis and management tools. It is designed to help users organize, analyze, and visualize data effectively. Stata 14 offers a user-friendly interface, advanced statistical methods, and powerful programming capabilities.
Sourced in United States, United Kingdom, Japan, Austria, Germany, Denmark, Czechia, Belgium, Sweden, New Zealand, Spain
SPSS version 25 is a statistical software package developed by IBM. It is designed to analyze and manage data, providing users with a wide range of statistical analysis tools and techniques. The software is widely used in various fields, including academia, research, and business, for data processing, analysis, and reporting purposes.

More about "Presenile Dementia"

Presenile Dementia, Early-Onset Dementia, Alzheimer's Disease, Vascular Disorders, Neurological Disorders, Cognitive Impairment, Personality Changes, Daily Activity Difficulties.
Presenile dementia is a form of dementia that occurs before the age of 65, often presenting with cognitive impairments, personality changes, and difficulties with daily activities.
This early-onset condition can have diverse etiologies, including Alzheimer's disease, vascular disorders, and other neurological disorders.
Accurate diagnosis and effective management of presenile dementia are crucial for improving patient outcomes and quality of life.
Research in this field aims to enhance understanding of risk factors, develop better diagnostic tools, and identify novel therapies to slow disease progression.
Statisticla software like SAS version 9.4, SAS 9.4, Stata version 14, Stata 15, Stata, SAS software, SAS v9.4, Stata 16, Stata 14, and SPSS version 25 can be utilized to analyze data and conduct studies related to presenile dementia.
These tools offer advanced statistical techniques and data visualization capabilities that can aid researchers in uncovering insights and patterns within presenile dementia datasets.
By leveraging these software platforms, researchers can enhance the quality and rigor of their studies, ultimately contributing to a better understanding of this complex condition and informing more effective treatment strategies.
However, it's important to note that the use of these statistical software packages requires proper training and expertise to ensure accurate analysis and interpretation of the results.